Global PharmaAccording to BioPharmaDive.com, “The FDA last week approved Amgen’ drug Kyprolis (Carfilzomib) for use in combination with other oncologic therapies, including Dexamethasone or Lenalidomide, for treatment of relapsed or multiple Myeloma…In addition, Amgen’s Repatha (Evolocumab) has been approved for treatment of specific types of Hypercholesterolemia in Japan—making it the first PCSK9 approved in Japan.”  For more information on this drug approval, please visit: http://www.biopharmadive.com/news/amgen-wins-big-with-kyprolis-expansion-in-us-and-repatha-approval-in-japan/412664/